Zepbound goes to $399 a month for people paying cash

Eli Lilly opened a cash lane for Zepbound on Tuesday, pricing the obesity medicine at $399 a month for people who are not using insurance. That is less than half the list price of other medicines used for obesity.

Cost and availability are the two things keeping these medicines away from the people who want them, and the program aims at both. The cash price reduces the monthly cost for anyone stepping outside coverage, and the discount rides on a different format: single-use vials drawn with a syringe rather than the auto-injector pen Zepbound normally ships in, which the company says will ease a supply constraint in the United States.

None of that is a trial result or a regulator's finding. It is a manufacturer's pricing decision paired with a manufacturer's promise, and the FDA has had the drug listed as in a shortage for most of the year, so more supply is what the vials are meant to deliver rather than what the counter shows. For a household paying out of pocket, $399 is a bill that returns every month, and anyone with insurance coverage sees none of this, because the number applies only outside it.

Read the full story at Forbes ↗

Retatrutide is investigational and is not FDA-approved. Other medicines referenced here are covered as third-party news for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.